

Prevalence of Metabolic Syndrome in Angiographically Confirmed Coronary Artery Disease

Alan Mobarek Mahmood, Mousa Haji Ahmed, Jamal Bashir Mohammad¹

Cardiac Center, Azadi Teaching Hospital, ¹Department of Internal Medicine, College of Medicine, University of Duhok, Duhok, Kurdistan, Iraq

Abstract

Background: Coronary artery disease (CAD) is one of the most common causes of death in the developed world with the high prevalence of cardiac risk factors and associated morbidity. These risk factors were mostly contributed in the metabolic syndrome. **Objective:** The study aimed to determine the prevalence of metabolic syndrome among patients with angiographically documented CAD and its relation with the severity of CAD. **Materials and Methods:** In the current cross-sectional study, a total of 320 patients aged 18 years and older of both genders and diagnosed with CAD by medical and clinical examinations and angiography findings were included in the study. Patients with normal angiographic or nonsignificant coronary stenosis and those with acute coronary syndrome were excluded from the study. **Results:** The prevalence of metabolic syndrome in patients diagnosed with CADs was 68.4% in this study. The numbers and severity of coronary arteries involved were importantly increased through increasing the numbers of the components of the metabolic syndrome that the patient have it. The majority of the patients with right coronary artery (67.6%), circumflex artery (63.2%), left anterior descending (66.7%), and multivessel (69.8%) had metabolic syndrome with no significant difference ($P = 0.913$). Moreover, the most of the patients with one vessel (66.4%), two vessels (68.2%), three vessels (72.2%), and four vessels (66.7%) were metabolic syndrome ($P = 0.846$). Between the individual components, diabetes mellitus (DM) was the most significant risk factor accounts for the number and severity of the CAD in all CAD patients. **Conclusions:** The prevalence of metabolic syndrome is high among patients with angiographically documented CAD. Patients having metabolic syndrome have more severe and more complex CAD.

Keywords: Comorbidity, coronary artery disease, metabolic syndrome

INTRODUCTION

The metabolic syndrome (syndrome X, insulin resistance syndrome) consists of a constellation of metabolic abnormalities that confer increased risk of cardiovascular disease (CVD) and diabetes mellitus (DM). The term “metabolic syndrome” was first used in the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) to describe the co-occurrence of obesity, dyslipidemia, hypertension (HT), and abnormal glucose metabolism (Expert Panel on Detection and Treatment of High Blood Cholesterol in 2001).^[1]

However, the association of metabolic disorders and cardiovascular risk factors had been recognized for many decades.^[2,3] In his American Diabetes Association Banting lecture in 1988, Reaven used the term “syndrome X” to describe the relationship of insulin resistance, HT, type 2

diabetes (T2D), and CVDs.^[4] Other investigators have referred to the clustering of metabolic and cardiovascular risk factors as the “insulin resistance syndrome.”^[5]

Coronary artery disease (CAD) is one of the most common causes of death in the developed world,^[6] the high prevalence of cardiac risk factors and associated morbidity have been reported in Iraqi adult population,^[7] these risk factors were mostly contributed in the metabolic syndrome, and it became a growing health problem in Iraq due to alteration in lifestyle, low physical activity, the epidemic of obesity and insulin resistance. Although in Iraq, little studies were found to identify the prevalence of the metabolic syndrome in patients

Address for correspondence: Dr. Alan Mobarek Mahmood, Azadi Teaching Hospital, Duhok, Kurdistan, Iraq. E-mail: alandusky2017@gmail.com

Access this article online

Quick Response Code:



Website:
www.medjbabylon.org

DOI:
10.4103/MJBL.MJBL_101_18

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Mahmood AM, Ahmed MH, Mohammad JB. Prevalence of metabolic syndrome in angiographically confirmed coronary artery disease. *Med J Babylon* 2018;15:310-5.

having CAD, and the majority of them accomplished among inpatients presenting with ACS before attending angiography catheterization, meanwhile they were an unconfirmed CAD.

Worldwide the prevalence of metabolic syndrome varies in part reflecting the age, ethnicity of their population and the diagnostic criteria applied, in general increases with age. The highest recorded prevalence was among native Americans 60% of women and 45% in men ages 45–59 years meeting criteria of the NCEP ATP III were as in the US, is less common in African–American men and more in Mexico–American woman based on data from the National Health and Nutrition Examination Survey 2003–2006. In France, studies of a cohort of 30–60 years have shown <10% prevalence for each sex although 17.5% of people 60–64 years of age were affected.^[8]

In a recent 2016 Iranian study among 200 CAD patients, the prevalence of metabolic syndrome was 49.5% women and 40% men.^[1] In Turkey reported a prevalence of 33.9%, The population for this analysis were 2108 men and 2151 women.^[9,10] In Tunisia, metabolic syndrome prevalence was 45.5% based on the IDF criteria and 24.3% according to the (ATP III) definition which included 3435 adults.^[11] In Palestinians, in East Jerusalem, metabolic syndrome was found in 115 (33.6%).^[12] In Northern Jordan, the prevalence of metabolic syndrome was 36.3%.^[13]

The aim of this study was to determine the prevalence of metabolic syndrome among patients with angiographically documented CAD and its relation with the severity of CAD.

MATERIALS AND METHODS

The cross-sectional prospective study enrolled all patients whom underwent elective coronary angiography in Azadi Heart Center/Duhok, Iraq, between September 2017 and May 2018.

The patient's ages were between 18 years and older of both genders, diagnosed with CAD by medical and clinical examinations and angiography findings. Patients with normal angiographic or nonsignificant coronary stenosis and those with acute coronary syndrome were excluded from the study.

Metabolic syndrome was diagnosed according to the ATP III criteria, including three or more of the following metabolic abnormalities: abdominal obesity (waist circumference [WC] >102 cm in men and >88 cm in women), high blood pressure (≥ 130 mmHg systolic or ≥ 85 mmHg diastolic), hypertriglyceridemia (>150 mg/dl, 1.7 mmol/L), low high density lipoprotein cholesterol (HDL-C) (<40 mg/dl, 1.03 mmol/L) in men and (<50 mg/dl, 1.29 mmol/L) in women, high fasting glucose (fasting serum glucose (>110 mg/dl)).^[14]

Diagnosis of patients with CAD was based on the result of coronary angiography, in which $>50\%$ stenosis regarded as significant vessel disease (VD), while those below this rate had been excluded from this study.^[14-16]

Statistical methods

The descriptive purposes of the study, including the prevalence of metabolic syndrome in CAD patients were determined in frequency and percentage. The continuous normally distributed characteristics of patients were determined in mean and standard deviation (SD). The difference of metabolic syndrome among angiography findings was examined in Chi-squared and Fishers' exact test. The predictors of angiography findings were examined in univariate analysis of variance. The null hypothesis was rejected in $P < 0.05$. The statistical calculations were performed using Statistical Package for the Social Sciences version 24 (SPSS, IBM Company, Chicago, USA).

RESULTS

The demographic and clinical characteristics of the 320 CAD patients (180 males and 140 females; aged 32–85 years, the mean age 57.74, SD: 9.96) with and without metabolic syndrome are presented in Table 1; of these, 68.4% had metabolic syndrome; (56.3% males vs. 52.1% females) ($P < 0.05$).

The majority of patients had abnormal high density lipid cholestetol (HDL-C), Triglyceride (TG), Waist circumference (WC), and were known diabetes mellitus DM or impaired fasting blood sugars (FBS) and hypertension (HT). For HDL.C (81.7% males and 73.6% females), for TG; (78.50%), WC; (77.9% females and 49.4 males), HT; (56.3% males and 43.8% females) while DM; 52% [Table 1].

Again the mean and percentages of WC, BMI, BP, FBS, TG, and low-density lipoprotein cholesterol ($P < 0.0001$) in CAD patients with metabolic Syndrome were significantly higher, and HDL-C levels ($P < 0.0001$) were significantly lower than in those without Metabolic Syndrome. Low serum HDL (36.28 ± 7.76 vs. 47.23 ± 9.64 , $P < 0.001$), high serum TG (227.89 ± 71.57 vs. 140.22 ± 56.36 , $P < 0.0001$), HT; 187 (85.8%) versus 25 (24.8%), $P (<0.0001)$, DM; 153 (70.2%) versus 15 (14.9%), $P (<0.0001)$, and they were the most significant risk factors for CAD in metabolic patients versus nonmetabolic ones [Table 2 and Figure 1].

The majority of the patients with right coronary artery (RCA) (67.6%), circumflex artery (CX) (63.2%), left anterior descending (LAD) (66.7%), and multivessel (69.8%) had metabolic syndrome with no significant difference ($P = 0.913$). Moreover, the most of the patients with 1 vessel (66.4%), two vessels (68.2%), three vessels (72.2%), and four vessels (66.7%) were metabolic syndrome ($P = 0.846$) [Table 3 and Figure 2].

Table 1: Prevalence of metabolic syndrome in coronary artery disease patients

Patients' characteristics	CAD (n=320)
Metabolic syndrome	
Yes	219 (68.4)
No	101 (31.6)

CAD: Coronary artery disease

Table 2: Baseline characteristics of metaboli and nonmetabolic patients (n=320)

Patients' characteristics (n=320)	MetS (n=219)	Non-MetS (n=101)	P (two-sided)
Age (year)	57.77±9.23	57.70±11.44	0.961*
Male	55.82±9.63	57.03±11.41	
Female	59.56±8.51	59.65±11.58	
HDL (mg/dL)	36.28±7.76	47.23±9.64	<0.0001*
Male, n (%)			
Normal	3 (2.9)	30 (40.0)	
Abnormal	102 (97.1)	45 (60.0)	
Female, n (%)			
Normal	17 (14.9)	20 (76.9)	
Abnormal	97 (85.1)	6 (23.1)	
TG (mg/dL)	227.89±71.57	140.22±56.36	<0.0001*
Normal, n (%)	30 (13.7)	71 (70.3)	
Abnormal, n (%)	189 (86.3)	30 (29.7)	
WC (cm)	102.85±10.08	91.67±10.26	<0.0001*
Male, n (%)			
Normal	29 (27.6)	62 (82.7)	
Abnormal	76 (72.4)	13 (17.3)	
Female, n (%)			
Normal	16 (14.0)	15 (57.7)	
Abnormal	98 (86.0)	11 (42.3)	
BMI	29.56±5.05	26.51±4.10	<0.0001*
Underweight, n (%)	1 (0.5)	0 (0.0)	
Normal weight, n (%)	22 (10.0)	16 (15.8)	
Overweight, n (%)	47 (21.5)	16 (15.8)	
Obese, n (%)	149 (68.0)	69 (68.3)	
Smoking, n (%)	80 (37.0)	50 (51.5)	0.016**
Gender, n (%)			<0.0001**
Males	105 (47.9)	75 (74.3)	
Female	114 (52.1)	26 (25.7)	
Hypertension, n (%)	187 (85.8)	25 (24.8)	<0.0001**
Male	81 (77.9)	14 (18.7)	
Female	106 (93.0)	11 (42.3)	
Diabetes mellitus, n (%)	153 (70.2)	15 (14.9)	<0.0001**
Male	64 (61.5)	12 (16.0)	
Female	89 (78.1)	3 (11.5)	
Family history, n (%)	81 (17.7)	65 (65.6)	<0.0001
Smokers	37% (117 male, 13 female)	51.50%	

*Independent t-test and **Chi-squared tests were performed for statistical analyses. HDL: High-density lipoprotein, TG: Triglyceride, WC: Waist circumference, BMI: Body mass index, MetS: Metabolic syndrome

The numbers and severity of coronary arteries involved were importantly increased through increasing the numbers of the components of the metabolic syndrome that the patient have it [Table 4], although not reaching the significant values, here the individual components such as obesity, HT, DM, dyslipidemias, smoking, and family history played there role in the pathogenicity of the nonmetabolic categorized CAD




Figure 1: Prevalence of individual components of metabolic syndrome.
*Gender represents males 1

patients.

Between the individual components, DM was the most significant risk factor accounts for the number and severity of the CAD in all CAD patients as follow: 2VD; (63 [37.5%] vs. 44 [29.1%], 3VD; (48 [28.6%] vs. 31 [20.5%]), ($P = 0.045$), multi-VD (MVD); (114 [67.9%] vs. 78 [51.7%]), ($P = 0.029$) as compression between diabetic and nondiabetic patients, respectively [Tables 4-6].

DISCUSSION

In this study, the prevalence of metabolic syndrome in angiographically confirmed CAD patients was 68.4% which is similar to studies in other regions of the world like in study by Achari *et al.*, in which prevalence was 64.2% in Indian population,^[17] while in Iranian adults the prevalence of metabolic syndrome among CAD patients was 49.5%.^[18] Furthermore, in Pakistani patients, the prevalence was much more less 37%.^[19]

Hence, the prevalence of Met S varies widely, depending on the type of study (hospital-based vs. population-based study), baseline characteristics of the study population (e.g., ethnicity, age, and history of ACS) and criteria used to define Met S. Furthermore, these differences could be due to lifestyle-related factors such as unhealthy food habits, urbanization, economic growth, physical inactivity and increased stress, high percentage of body fat, and abdominal obesity.

The individual components of the metabolic syndrome whether alone or in combination with risk factors have variable effects on CAD risk with some of them having the highest risk for CAD, however, each component acts as an independent risk factor for CAD, but all of them interact synergistically, and thus lead to increased risk of CAD.^[6]

The prevalence of metabolic syndrome and its individual components with various rates in CAD patients has been reported in earlier studies, the abdominal obesity, dyslipidemia, HT, and hyperglycemia most often were reported as the metabolic syndrome components, and the severity of CAD increased with the number of components.^[20-23]

In Shanghai, a study performed and showed that among individual components of metabolic syndrome, low HDL,

high FBG, and high BP had the highest OR for coronary heart disease, these three parameters had significant increases in number of disease vessel.^[24]

In Korean population, a study showed that metabolic syndrome was independently linked to coronary parameters including obstructive plaque and coronary artery calcium score in the nondiabetic CAD patients, low HDL-C levels were markedly associated with CAD among the individual components of metabolic syndrome in these patients.^[25,26]

However, there were no exact prevalence of metabolic syndrome in Iraq and or Kurdistan region, have been done before, and exactly in angiographic profile CAD patients, our results were near the results done in the Middle East countries.^[27,28]




Figure 2: Prevalence of metabolic syndrome in angiography findings (vessel number)

Table 3: Angiography findings of coronary artery disease patients

Angiography findings of CAD patients (n=320)	Frequency distribution		P (two-sided)
	MetS (n=219), n (%)	Non-MetS (n=101), n (%)	
RCA	25 (11.4)	12 (11.9)	0.913 (Chi-squared test)
CX	12 (5.5)	7 (6.9)	
LAD	48 (21.9)	24 (23.8)	
Multivessel (69.8%)	134 (61.2)	58 (57.4)	
Vessel numbers			
1 vessel (66.4%)	85 (38.8)	43 (42.6)	0.859 (Chi-squared test)
2 vessels (68.2%)	73 (33.3)	34 (33.7)	
3 vessels (72.2%)	57 (26.0)	22 (21.8)	
4 vessels (66.7%)	4 (1.8)	2 (2.0)	

RCA: Right coronary artery, CX: Circumflex artery, LAD: Left anterior descending artery, CAD: Coronary artery disease, MetS: Metabolic syndrome

Unfortunately, in our study, the premature CAD was obvious in which the mean age were (57.77 ± 9.23) and (57.70 ± 11.44) for metabolic and nonmetabolic patients respectively, and the females were older than males by (4 years) [Table 2].

Concerning the gender, in our study, the prevalence of metabolic syndrome in female patients who present with CAD was higher when compared with overall cohort studies,^[28-30] had shown a higher prevalence of metabolic syndrome in female presenting with ACS.

Among the individual components of metabolic syndrome, nearly all components, DM, HT, hypertriglyceridemia (TG), and HDL-C, central obesity (WC), were significantly abnormal ($P < 0.0001$), as compared with nonmetabolic syndrome patients.

Females were more diabetic, hypertensive, obese, hypertriglyceridemia, less or passive smokers, and older. While males were more smokers, thinner, and younger in ages due to cultural habits.

Nonmetabolic patients were mostly males, more smokers, and mostly were diabetic, hypertensive, and had low (HDL-C), and had a family history of CAD.

Regarding the association of high-level glucose, some studies have shown markedly associated with CAD. A study reported that the prevalence of CHD in diabetic patients with metabolic syndrome was significantly higher than in those without metabolic syndrome.^[31]

The severity, the pattern of the lesion and characteristics type of coronary vessel involved in both metabolic and nonmetabolic syndrome patients, were studied, and it revealed that MVD; (2VD), (3VD), were more prevalent in metabolic syndrome group than those without metabolic syndrome (57.4% vs. 42.6%).

Similar observations had been reported by other studies. Kip *et al.*^[32] reported statistically significant prevalence of severe CAD in patients with Met S (47% as compared to 25% in patients without Met S). Yavuz *et al.*^[33] reported significantly higher number of patients with Met S having severe CAD as compared to patients without Met S (91% vs. 62%)^[34] in a multicenter study also reported significantly higher prevalence of severe CAD in European American and African American patients having Met S as compared to patients without Met S (71% and 57% vs. 29% and 43%).

Table 4: Severity of coronary artery disease according to components of metabolic syndrome

Number of metabolic components	Single vessel disease	Double vessel disease	Triple vessel disease	Four vessel disease	P
0	2 (28.6)	2 (28.6)	3 (42.9)	0 (0.0)	0.670**
1	10 (40.0)	9 (36.0)	5 (20.0)	1 (4.0)	0.814*
2	17 (41.5)	14 (34.1)	9 (22.0)	1 (2.4)	0.968*
3	33 (49.3)	16 (23.9)	18 (26.9)	0 (0.0)	0.130**
4	49 (37.7)	49 (37.7)	30 (23.1)	2 (1.5)	0.617**
5	17 (34.0)	17 (34.0)	14 (28.0)	2 (4.0)	0.526*

*Chi-square and **Fisher's exact tests were performed for statistical analyses

Table 5: Univariate analysis of variance of angiography results

Dependent variable: Angiography vessel number			Dependent variable: Angiography findings	
Predictors	F score	P	F score	P
Smoking	0.046	0.831	0.062	0.804
Gender	2.450	0.119	1.553	0.214
DM	4.065	0.045	6.323	0.013
Metabolic	0.258	0.612	0.108	0.743
Age	1.112	0.296	0.821	0.793

The bold numbers show the significant predictors. DM: Diabetes mellitus

Table 6: Angiography findings between diabetic and nondiabetic patients

Angiography findings	DM		P (two-sided)
	Yes (%)	No (%)	
Angiography results			
RCA	16 (9.5)	21 (13.9)	0.029
CX	7 (4.2)	12 (7.9)	
LAD	31 (18.5)	40 (26.5)	
Multi-vessel	114 (67.9)	78 (51.7)	
Angiography results (vessel number)			
1 vessel	54 (32.1)	73 (48.3)	0.029
2 vessels	63 (37.5)	44 (29.1)	
3 vessels	48 (28.6)	31 (20.5)	
4 vessels	3 (1.8)	3 (2.0)	

RCA: Right coronary artery, CX: Circumflex artery, LAD: Left anterior descending artery, DM: Diabetes mellitus

LAD artery was mostly diseased followed by (RCA) and (CX) nearly equally in both groups. Complex coronary lesions (diffuse and tubular) were more in metabolic syndrome group as compared to simple (discrete) lesions in nonmetabolic syndrome group. Our angiography findings were in accordance with observations.^[35,36]

CONCLUSIONS

The prevalence of metabolic syndrome is high among patients with angiographically documented CAD. Patients having metabolic syndrome have more severe and more complex CAD.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). *JAMA* 2001;285:2486-97.

- Albrink MJ, Krauss RM, Lindgren FT, von der Groeben J, Pan S, Wood PD. Intercorrelations among plasma high density lipoprotein, obesity and triglycerides in a normal population. *Lipids* 1980;15:668-76.
- Sarafidis PA, Nilsson PM. The metabolic syndrome: A glance at its history. *J Hypertens* 2006;24:621-6.
- Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes* 1988;37:1595-607.
- DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. *Diabetes Care* 1991;14:173-94.
- Fiuzza M. Metabolic syndrome and coronary artery disease. *Rev Port Cardiol* 2012;31:779-82.
- Al-Rubaye FG. Frequency of metabolic syndrome in a sample of adult diabetics in Baghdad. *Iraqi J Community Med* 2011;24:12-6.
- Malani PN. Harrison's principles of internal medicine. *JAMA* 2013;308:1813-4.
- Sanisoglu SY, Oktenli C, Hasimi A, Yokusoglu M, Ugurlu M. Prevalence of metabolic syndrome-related disorders in a large adult population in Turkey. *BMC Public Health* 2006;6:92.
- Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, *et al.* Prevalence of the Metabolic syndrome among Turkish adults. *Eur J Clin Nutr* 2007;61:548-53.
- Bouguerra R, Alberti H, Smida H, Salem LB, Rayana CB, El Atti J, *et al.* Waist circumference cut-off points for identification of abdominal obesity among the Tunisian adult population. *Diabetes Obes Metab* 2007;9:859-68.
- Abu Sham'a RA, Darwazah AK, Kufri FH, Yassin IH, Torok NI. MetS and cardiovascular risk factors among palestinians of East Jerusalem. *East Mediterr Health J* 2009;15:1464-73.
- Khader Y, Bateiha A, El-Khateeb M, Al-Shaikh A, Ajlouni K. High prevalence of the Metabolic syndrome among Northern Jordanians. *J Diabetes Complications* 2007;21:214-9.
- Miller JM, Dewey M, Vavere AL, Rochitte CE, Niinuma H, Arbab-Zadeh A, *et al.* Coronary CT angiography using 64 detector rows: Methods and design of the multi-centre trial CORE-64. *Eur Radiol* 2009;19:816-28.
- Cury RC, Ferencik M, Achenbach S, Pomerantsev E, Nieman K, Moselewski F, *et al.* Accuracy of 16-slice multi-detector CT to quantify the degree of coronary artery stenosis: Assessment of cross-sectional and longitudinal vessel reconstructions. *Eur J Radiol* 2006;57:345-50.
- Raff GL, Abidov A, Achenbach S, Berman DS, Boxt LM, Budoff MJ, *et al.* SCCT guidelines for the interpretation and reporting of coronary computed tomographic angiography. *J Cardiovasc Comput Tomogr* 2009;3:122-36.
- Achari V, Thakur A, Sinha AK. The metabolic syndrome – Its prevalence and association with coronary artery disease in type 2 diabetes. *J Indian Acad Clin Med* 2006;7:32-8.
- Montazerifar F, Bolouri A, Mahmoudi Mozaffar M, Karajibani M. The prevalence of metabolic syndrome in coronary artery disease patients. *Cardiol Res* 2016;7:202-8.
- Wierzbicki AS, Nishtar S, Lumb PJ, Lambert-Hamill M, Turner CN, Crook MA, *et al.* Metabolic syndrome and risk of coronary heart disease in a Pakistani cohort. *Heart* 2005;91:1003-7.
- Lopes NH, Paulitsch FS, Pereira AC, Góis AF, Gagliardi A, Garzillo CL, *et al.* Impact of Metabolic syndrome on the outcome of patients with stable coronary artery disease: 2-year follow-up of the MASS II study. *Coron Artery Dis* 2008;19:383-8.
- Amarasinghe S, Sandrasegarampillai B, Arasaratnam V. Metabolic syndrome among Jaffna Tamil community, Sri Lanka. *Indian J Endocrinol Metab* 2015;19:663-6.
- Hajian-Tilaki K. Metabolic syndrome and its associated risk factors in Iranian adults: A systematic review. *Caspian J Intern Med* 2015;6:51-61.
- Moussouami SI, Bouhika EJ, Nsompfi F, Kayilou JM, Mbemba F, Massamba A. Prevalence and risk factors of cardiovascular diseases in the Congo-Brazzaville Pygmies. *World J Cardiovasc Dis* 2016;6:211.
- Zhang Y, Hong J, Gu W, Gui M, Chen Y, Zhang Y, *et al.* Impact of the Metabolic syndrome and its individual components on risk and severity of coronary heart disease. *Endocrine* 2009;36:233-8.
- Won KB, Chang HJ, Kim HC, Jeon K, Lee H, Shin S, *et al.* Differential impact of metabolic syndrome on subclinical atherosclerosis according

- to the presence of diabetes. *Cardiovasc Diabetol* 2013;12:41.
26. Won KB, Chang HJ, Sung J, Shin S, Cho IJ, Shim CY, *et al.* Differential association between metabolic syndrome and coronary artery disease evaluated with cardiac computed tomography according to the presence of diabetes in a symptomatic Korean population. *BMC Cardiovasc Disord* 2014;14:105.
 27. Agoșton-Coldea L, Mocan T, Rusu LD, Pais R, Albu A, Rusu ML, *et al.* The impact of the metabolic syndrome on the patients with acute coronary syndrome. *Rom J Intern Med* 2008;46:55-62.
 28. Al Suwaidi J, Zubaid M, El-Menyar AA, Singh R, Rashed W, Ridha M, *et al.* Prevalence of the metabolic syndrome in patients with acute coronary syndrome in six middle Eastern countries. *J Clin Hypertens (Greenwich)* 2010;12:890-9.
 29. Gupta A, Gupta R, Sarna M, Rastogi S, Gupta VP, Kothari K. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an Urban Indian population. *Diabetes Res Clin Pract* 2003;61:69-76.
 30. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome in Urban Asian Indian adults – A population study using modified ATP III criteria. *Diabetes Res Clin Pract* 2003;60:199-204.
 31. Alexander CM, Landsman PB, Teutsch SM, Haffner SM; Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined Metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. *Diabetes* 2003;52:1210-4.
 32. Kip KE, Marroquin OC, Kelley DE, Johnson BD, Kelsey SF, Shaw LJ, *et al.* Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: A Report from the Women's Ischemia syndrome Evaluation (WISE) study. *Circulation* 2004;109:706-13.
 33. Yavuz B, Kabakci G, Aksoy H, Tulumen E, Deveci OS, Aytemir K, *et al.* Determining the relationship between metabolic syndrome score and angiographic severity of coronary artery disease. *Int J Clin Pract* 2008;62:717-22.
 34. Anuurad E, Chiem A, Pearson TA, Berglund L. Metabolic syndrome components in African-Americans and European-American patients and its relation to coronary artery disease. *Am J Cardiol* 2007;100:830-4.
 35. Henry P, Makowski S, Richard P, Beverelli F, Casanova S, Louali A, *et al.* Increased incidence of moderate stenosis among patients with diabetes: Substrate for myocardial infarction? *Am Heart J* 1997;134:1037-43.
 36. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. *Indian J Med Res* 2007;125:217-30.

